These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 34486981)

  • 1. Nonalcoholic steatohepatitis: global impact and clinical consequences.
    Kabarra K; Golabi P; Younossi ZM
    Endocr Connect; 2021 Oct; 10(10):R240-R247. PubMed ID: 34486981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 4. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
    Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
    J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis.
    Sayiner M; Lam B; Golabi P; Younossi ZM
    Therap Adv Gastroenterol; 2018; 11():1756284818811508. PubMed ID: 30479664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease.
    Iqbal U; Perumpail BJ; Akhtar D; Kim D; Ahmed A
    Medicines (Basel); 2019 Mar; 6(1):. PubMed ID: 30889791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
    Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
    World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies.
    Golabi P; Owrangi S; Younossi ZM
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1():S1-S9. PubMed ID: 38813821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Younossi Z; Tacke F; Arrese M; Chander Sharma B; Mostafa I; Bugianesi E; Wai-Sun Wong V; Yilmaz Y; George J; Fan J; Vos MB
    Hepatology; 2019 Jun; 69(6):2672-2682. PubMed ID: 30179269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic Steatohepatitis: A Review.
    Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
    JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Younossi ZM; Loomba R; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Chalasani NP; Anstee QM; Kowdley KV; George J; Goodman ZD; Lindor K
    Hepatology; 2018 Jul; 68(1):361-371. PubMed ID: 29222911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.
    Hassen G; Singh A; Belete G; Jain N; De la Hoz I; Camacho-Leon GP; Dargie NK; Carrera KG; Alemu T; Jhaveri S; Solomon N
    Cureus; 2022 May; 14(5):e25495. PubMed ID: 35783879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH.
    Stine JG; Schreibman I; Navabi S; Kang M; Dahmus J; Soriano C; Rivas G; Hummer B; Beyer M; Tressler H; Kimball SR; Patterson AD; Schmitz K; Sciamanna C
    Contemp Clin Trials Commun; 2020 Jun; 18():100560. PubMed ID: 32309672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
    Younossi ZM; Koenig AB; Abdelatif D; Fazel Y; Henry L; Wymer M
    Hepatology; 2016 Jul; 64(1):73-84. PubMed ID: 26707365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.